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Pancreatic cancerIt is a therapeutic strategy for cancers including pancreatic to inhibit proteasome activity. Disulﬁram (DSF) may
bind copper (Cu) to form aDSF–Cu complex. DSF–Cu is capable of inducing apoptosis in cancer cells by inhibiting
proteasome activity. DSF is rapidly converted to diethyldithiocarbamate (DDTC) within bodies. Copper(II)
absorbed by bodies is reduced to copper(I) when it enters cells. We found that DDTC and copper(I) could form
a binuclear complex which might be entitled DDTC–Cu(I), and it had been synthesized by us in the laboratory.
This study is to investigate the anticancer potential of this complex on pancreatic cancer and the possible mech-
anism. Pancreatic cancer cell lines, SW1990, PANC-1 and BXPC-3 were used for in vitro assays. Female athymic
nudemice grown SW1990 xenografts were used as animalmodels. Cell counting kit-8 (cck-8) assay and ﬂow cy-
tometry were used for analyzing apoptosis in cells. A 20S proteasome assay kit was used in proteasome activity
analysis. Western blot (WB) and immunohistochemistry (IHC) and terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) assayswere used in tumor sample analysis. The results suggest thatDDTC–Cu(I) inhib-
it pancreatic cancer cell proliferation and proteasome activity in vitro and in vivo. Accumulation of ubiquitinated
proteins, and increased p27 as well as decreased NF-κB expression were detected in tumor tissues of DDTC–
Cu(I)-treated group. Our data indicates that DDTC–Cu(I) is an effective proteasome activity inhibitor with the po-
tential to be explored as a drug for pancreatic cancer.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Cancer cells aremore sensitive than normal cells to proteasome inhi-
bition, and the proteasome-mediated degradation pathway is consid-
ered an important target for cancer treatment (Chen et al., 2006). The
proteasome inhibitor bortezomib has been reported to inhibit tumor ac-
tivity in a variety of cancer models, whichwas approved by the US Food
and Drug Administration (FDA) for clinical treatment in multiple mye-
loma (MM) (Kane et al., 2006), bringing investigator conﬁdence onoad, Shanghai 200031, China.
ve Oncology, Fudan University
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. Open access under CC BY-NC-ND liceinhibition of this pathway. Though copper (Cu) is an essential cofactor
for tumor angiogenesis processes, some copper complexes demonstrate
the capacity to inhibit proteasome activity, inducing apoptosis in vari-
ous types of human cancer cells. Disulﬁram (DSF) used clinically as an
alcohol deterrent in theUSA, is capable of binding copper to form a com-
plex named DSF–Cu which acts as a proteasome inhibitor preferable to
cancer cells (Chen et al., 2006).
Copper is largely absorbed from the stomach and the small intes-
tine. Absorbed copper is transported to the liver in portal blood
bound to albumin and is transmitted to peripheral tissues mainly
bound to ceruloplasmin and, to a lesser extent, albumin. During the
process of cellular copper uptake, copper enters the cell through var-
ious transmembrane transporters and copper(II) is reduced to
copper(I) (Knopfel and Solioz, 2002; McKie et al., 2001). In vivo,
DSF is rapidly converted to its reduced metabolite, DDTC (Escarabajal
and Aragon, 2003; Pike et al., 2001), and if copper ions are available,
DDTC–Cu(I) or –Cu(II) complex will be formed (Fig. 1). As other inves-
tigators described (Chen et al., 2006; Iljin et al., 2009), the activity of DSF
to inhibit the cellular proteasome in vivo might be attributed to DDTC–
Cu complexes.nse.
Fig. 1. Disulﬁram (DSF) molecule can undergo de-oxidation and transform into diethyldithiocarbamate (DDTC) which can react with metals to form coordination complexes.
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activity inhibitor in cancer cells The present study is focused onwhether
DDTC–Cu(I) has the potential to induce apoptosis in pancreatic cancer
cultures and xenografts by inhibiting proteasome activity. Though
DDTC–Cu complex has been reported by other investigators before
(Pang et al., 2007), their studies described the copper(II) complexmainly
and this article is the ﬁrst to describe the copper(I) complex especially to
the best of our knowledge.
Materials and methods
Cell lines and reagents. The human pancreatic cancer cell lines,
SW1990, PANC-1 and BXPC-3, were originally obtained from the ATCC
(American Type Culture Collection, Manassas, VA, USA). Cells were
grown in RPMI 1640 supplemented with 10% fetal bovine serum (FBS).
All cells were maintained at 37 °C and 5% CO2, and used at early passage
numbers (passage 3–6). Sodium diethyldithiocarbamate trihydrate (C-
5H10NS2·Na·3H2O), copper chloride dihydrate (CuCl2·2H2O), and sodi-
um sulﬁte (Na2SO3) were purchased from Sigma-Aldrich Corp. (MO,
USA). The 20S proteasome assay kit was purchased from Enzo Life Sci-
ences, Inc. (NY, USA). The rabbit polyclonal antibodies against human
ubiquitin or NF-κB p50, and a mouse monoclonal antibody against
human p27 were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). RPMI 1640 and fetal bovine serumwere obtained
from Invitrogen (Carlsbad, CA, USA).
Chemical synthesis. The DDTC–Cu(I) complex for cell or animal
treatment was synthesized at a concentration of 1 mmol/L as per
the quantity equivalent to the molar quantity of DDTC or copper
(all the concentrations to describe DDTC–Cu(I) were equivalent to
the molar quantity of DDTC or copper in this article). First, sodium
diethyldithiocarbamate trihydrate or copper chloride dihydrate as
well as sodium sulﬁte was dissolved in sterilized water to produce
a solution of 200 mmol/L concentration respectively. Second, a total of
50 μL of a sodium diethyldithiocarbamate solution, 25 μL of a sodium
sulﬁte and 50 μL of a copper chloride which were prepared in the ﬁrst
step were added to 9 mL of sterilized water orderly and mixed gently.
The third, sterilized water was then added to the prepared solution to
ensure that the solution had a total volume of 10 mL, and the solution
was gently mixed again. Finally, the complex solution was packed and
stored at 4 °C.
Cell proliferation assay. Cellular proliferation was assessed by qua-
druplicate plating at a density of 5000 cells per well in a 96-well plate.
The designated concentrations of fresh media containing the drugs or
the vehicle were added to cell cultures containing the standard growth
media for that cell line on the morning after plating for 12 h once the
cells had attached. Viable cells were quantiﬁed after the 24-hourtreatments using cell counting kit-8 (cck-8) reagent (Dojindo Laborato-
ries, Kumamoto, Japan) according to the manufacturer's protocol. The
cck-8 solution (10 μL) was added to each well, followed by incubation
for 2 h at 37 °C. The absorbance at 450 nm was determined using an
ELx800 Absorbance Microplate Reader (Bio-TEK Instruments Inc.,
Winooski, VT, USA). Cell viability was expressed as a percentage of
that of the control (untreated) cells. For each concentration of the com-
plex, themean value of themean absorbance from fourwells was calcu-
lated. IC50 value was calculated from a sigmoidal dose–response curve
ﬁt using Prism GraphPad 5 Demo (GraphPad Software, CA, USA).
Flow cytometric apoptosis assay. An Alexa Fluor® Annexin V/Dead
Cell Apoptosis kit (Invitrogen, CA, USA) was used, according to the
manufacturer's instructions, to distinguish and quantitatively determine
the percentage of apoptotic cells after treatment by the drugs. Cells were
seeded at a density of 4 × 105 cells/mL in 6-well plates. After treatment,
the cells were harvested, washed twice with ice-cold phosphate-
buffered saline (PBS), and resuspended in 100 μL of binding buffer. A
total of 5 μL of Annexin V and 10 μL of propidium iodide (PI) were
added, and the mixture was incubated for 30 min in the dark. Finally,
400 μL of binding buffer was added to the cells. The labeled cells
(10,000 per sample at least) were analyzed by measuring the ﬂuores-
cence intensity using a FC500 MPL cytometer (Beckman Coulter Inc.,
Brea, CA, USA) in conjunction with CXP analysis software (Beckman
Coulter Inc.).
20S proteasome activity assay. A total of 17.5 ng of 20S proteasome
(human) was incubated in 100 μL of assay buffer with or without dif-
ferent concentrations of the DDTC–Cu(I) complex, copper chloride,
sodium sulﬁte, DDTC, or their combinations, and 10 μmol/L of the
ﬂuorogenic peptide substrate Suc-LLVY-AMC for 2 h at 37 °C. After
incubation, the production of hydrolyzed AMC groups was measured
with a Synergy H4 Hybrid Multi-Mode Microplate Reader (Bio-TEK
Instruments Inc., Winooski, VT, USA) with an excitation ﬁlter of
365 nm and an emission ﬁlter of 460 nm. Whole-cell extracts
(10 μg) of cells treated as indicated were incubated for 1 h at 37 °C
in 100 μL of assay buffer with 20 μmol/L ﬂuorogenic substrate
(Chen et al., 2006).
Xenograft experiment. Five-week-old female athymic nudemicewere
purchased from the Shanghai Laboratory Animal Center (Chinese Acad-
emy Science) and housed under speciﬁc pathogen-free conditions
according to Fudan University animal care guidelines. The experimental
animal protocols were reviewed and approved by the animal care com-
mittee of the Shanghai Institutes for Biological Sciences of the Chinese
Academy of Sciences and the Fudan University Shanghai Cancer Center.
Mice were maintained in laminar ﬂow rooms under constant tempera-
ture and humidity.
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subcutaneously into one ﬂank of each mouse. After 3 weeks, the mice
were sacriﬁced, and tumors were harvested. Two tumors of medium
size were dissected to 1-mm3 volumes and transplanted into 16 mice.
After another 2 weeks, the mice showing tumors were randomly
assigned to the control group (n = 8) or the treatment (n = 8). The
followingmanagementswere administered: (a) control: received an in-
jection of dexamethasone, 0.5 mg/kg, intra-peritoneally (i.p.), every
other day (qod); (b) treatment: received 10 nmol/g DDTC–Cu(I) as
well as 0.5 mg/kg dexamethasone, i.p., qod. The concentration of
DDTC–Cu(I) used was 1 mmol/L. Tumor sizes were measured every
3 days, and tumor volumes (V) were determined by the equation
V = (L × W2) × 0.5, where L was the length and W was the width of
tumors (Jimeno et al., 2009). The mice were treated for 25 days and
sacriﬁced on the 25th day. The tumors were then removed and
photographed. Tumor tissues were ﬁxed in formalin for hematoxylin
and eosin (H&E), immunohistochemical (IHC) staining, and TUNEL
assay.
H&E staining, IHC and TUNEL assays. For H&E staining, parafﬁn-
embedded sample slides were deparafﬁnized, hydrated, and then
stained with hematoxylin for 1 min. After rinsing, the slides were
stained with eosin for 1 min, rinsed, and sealed with cover slips using
Permount. For IHC staining, endogenous peroxidase was blocked with
3% hydrogen peroxide, and the slideswere then incubatedwith the pri-
mary anti-human antibodies, anti-p27 (Santa Cruz), anti-NF-κB p50
(Santa Cruz) and anti-ubiquitin (Santa Cruz). The slides were then ex-
posed to horseradish peroxidase-conjugated anti-digoxigenin sec-
ondary antibodies (Roche Applied Science, Mannheim, Germany)
and 3,3′-diaminobenzidine-tetrahydrochloridedihydrate (DAB; Dako,
Glostrup, Denmark) as a chromogen. The TUNEL assay was performed
using an Apotag kit (Roche Applied Science, Mannheim, Germany).
Staining was performed by a pathologist in a blinded fashion with
coded samples.
Western blotting analysis. Tumor tissues were homogenized on ice in
extraction buffer using a micro-pestle. The lysate was then centrifuged
at 10,000× g for 10 min at 4 °C and the supernatants were collected.
Equal amounts of protein were separated by SDS-PAGE and transferred
to a nitrocellulose membrane. Western blot (WB) analysis was
performed using speciﬁc antibodies (Santa Cruz) against p27, NF-κB
p50, ubiquitin or GAPDH. Horseradish peroxidase-conjugated second-
ary antibodies and the SuperSignal West Pico Chemiluminiscent sub-
strate (Pierce Biotechnology Inc., IL, USA) were used to develop blots.
Determination of copper contents in tissues. To determine copper con-
tents in tumors harbored by mouse as well as organs such as brains,
livers and kidneys of the control or the treated group, 0.5–1.0 g of sam-
ples were placed in beakers with 5 mL of concentrated nitric acid and
dried by heating in a fume cupboard (Kurasaki et al., 1998). The samplesFig. 2. Concentration–effect curves used forwere transferred to a mufﬂe furnace and incinerated at 450–500 °C for
4 h. The residues were dissolved with 2 mL aqua regia, and the copper
in resolution was determined with an inductively coupled atomic ab-
sorption spectrometer (ICP-AAS, Model Z-5000, Hitachi, Tokyo, Japan).
Statistics. The quantitative results are represented as the mean ±
standard error of at least three independent experiments. Signiﬁcant
differences were determined with the two-tailed Student's t test using
Ofﬁce Excel 2003 or GraphPad Prism 5 Demo (GraphPad Software, San
Diego, CA, USA). P-values b0.05were considered statistically signiﬁcant.
Results
DDTC–Cu(I) induces apoptosis in pancreatic cancer cells
Based on the cck-8 assay, the 24-hour IC50 values of DDTC–Cu(I)
for the three cell lines, SW1990, PANC-1 and BXPC-3, calculated
were 0.59, 0.58, 0.61 μmol/L, respectively (Fig. 2). At a concentration
of 5 μmol/L, DDTC–Cu(I) could effectively inhibit the proliferation of
the three cell lines in vitro, but the precursors of this complex, i.e.
DDTC, CuCl2, Na2SO3, or their combinations, i.e. CuCl2 + Na2SO3
(2:1), DDTC + Na2SO3 (2:1) could not (Fig. 3A).
AnnexinV/PI bindingwas used to distinguish between the inductions
of apoptosis versus necrosis. Different staining patterns in this assay en-
abled us to identify different cell populations: live cells (Annexin V-
negative/PI-negative), early apoptotic cells (Annexin V-positive/PI-nega-
tive), late apoptotic/necrotic cells (Annexin V-positive/PI-positive), and
dead cells (Annexin V-negative/PI-positive). The ﬂow cytometry results
showed that DDTC–Cu(I) at concentrations of 1, 3 or 5 μmol/L signiﬁ-
cantly increased apoptosis in SW1990 cells (Fig. 3B).
As shown in Fig. 2B, around 55% SW1990 cells remained alive after
the 24-hour treatment with 5 μM DDTC–Cu(I). However, the cck-8
assay showed that the same treatment was capable of killing approxi-
mately 95% of the cells. This discrepancymight result from the different
culture conditions involving the different numbers of cells plated or cul-
ture plates that 96-well ones were used in the former while 6-well ones
in the latter as well as different assay systems. The cck-8 assay results
should be more reliable than those from the ﬂow cytometry. That may
be veriﬁed by a morphological analysis. As shown in Fig. 3C, after the
24-hour treatment, DDTC–Cu(I) induced apparent cell shrinkage and
cell rounding at 1 μmol/L and further induced extensive cell rounding
and condensed morphology at 3 to 5 μmol/L, few living cells were ob-
served. These data suggest that the DDTC–Cu(I) complex has a signiﬁ-
cant apoptosis-inducing effect in pancreatic cancer cells.
DDT–Cu(I) inhibits proteasome activity
A cell-free proteasome activity assay was done with the following
three kinds of chemicals, i.e. DDTC, CuCl2 and Na2SO3, and their dif-
ferent mixtures, i.e. CuCl2 + Na2SO3 (2:1), DDTC + Na2SO3 (2:1)IC50 calculation. Treatment time, 24 h.
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chymotrypsin-like (CT-like) activity of the puriﬁed human 20S
proteasome was inhibited to a similar level by all of the treatments
containing copper (Fig. 4A), while it was not by others without cop-
per, indicating that copper is the essential role for the complex as a
proteasome activity inhibitor.
To further examine this effect of DDTC–Cu(I), SW1990 cells were
treatedwith the complex at concentrations of 1, 3, 5 μmol/L and the ve-
hicle. After 24 h, the cells were collected, and lysates were prepared to
measure proteasome inhibition as shown by decreased levels of the
proteasomal CT-like activity. The results showed that proteasomal
CT-like activities were decreased by around 8%, 70% and 94% in the
cancer cells treated by 1, 3 and 5 μmol/L DDTC–Cu(I), respectively,
compared with the vehicle-treated cells (Fig. 4B). Based on morpho-
logical analysis, cells treated by 5 μmol/L DDTC–Cu(I) were mostly
dead. Taken together, the results indicate that the complex is capable
of inducing apoptosis in cancer cells via inhibiting proteasome
activity.DDTC–Cu(I) arrests the tumorigenesis of pancreatic cancer cells in vivo
The mice harboring SW1990 cell xenografts were treated with
DDTC–Cu(I), and dexamethasone was used to reduce the adverse effects
of the treatment. During the 25-daymanagement, only onemouse in the
treatment group died (on day 17), and the others survived to the end of
the experiment. According to the tumor volumes measured on the 25th
day, the tumor growth in the treatment group was inhibited by 62.8%
(P b 0.01) compared with the control (Fig. 5A). Meantime, the growth
inhibition was reﬂected by tumor weights (Fig. 5B).Fig. 3. The effects of DDTC–Cu(I) on pancreatic cancer cell lines. A. Cck-8 assay. SW1990, PAN
DDTC + Na2SO3, CuCl2, DDTC or Na2SO3 for 24 h, followed by the cck-8 assay as described in
*P b 0.01 versus the control. B. Annexin V/PI double stainingwasmeasured after 0, 1, 3, 5 μMD
are alive, cells in the lower right quadrant are in early apoptosis, cells in the upper right quadr
changes (spherical and detached) were photographed under a microscope after 24 h of the inApoptosis occurred more frequently in tissues derived from xeno-
grafts in mice that received DDTC–Cu(I) treatment than that in mice
treated by dexamethasone alone as detected by the TUNEL assay
(48.7 ± 5.2% versus 3.4 ± 0.7%). Apoptosis induction in tumor samples
was also observed in theH&E staining. In contrast, apoptosiswasnot ap-
parent in the control xenograft tumors (Fig. 5C).
The stabilization of ubiquitinated proteins and p27 as well as the in-
hibition of NF- B activation are described as the effects of proteasome in-
hibitors (McDade et al., 1999; Zavrski et al., 2007). The increased
accumulation of ubiquitinated proteins, and up-regulated expression
of p27 and or the down-regulated of NF- B in DDTC-Cu(I)-treated
group were observed by WB assay and conﬁrmed by IHC compared to
the control (Figs. 5C and D), indicating that DDTC–Cu(I) might arrest
the tumorigenesis of pancreatic cancer cells via inhibiting proteasome
activity in vivo.Copper level keeps stable relatively within treated mice bodies
The tissue copper content analysis results showed that copper con-
tents in the tumors harbored by mice administered DDTC–Cu(I) in-
creased, meantime, copper contents in the brains, the livers, as well as
the kidneys of the treated group mice increased also compared with
the control group (Fig. 6). Among the tissues, the copper level of tumors
is higher than in the three organs, suggesting that copperwas enriched in
tumor tissues and the amount might be evenmore than that in the liver
which is the organ that stores copper within mammal bodies. Further-
more, we could ﬁnd that the copper levels in either the treated or the
control group were not increased as dramatically as that in the cases of
Wilson disease (Suzuki, 1995; Shim and Harris, 2003), indicating thatC-1 and BXPC-3 cell lines were treated with 5 μmol/L of DDTC–Cu (I), CuCl2 + Na2SO3,
Materials and methods. Columns, the mean cell viability of the three cell lines; bars, SD.
DTC–Cu(I) treatment in SW1990 cells for 24 h. In all panels, cells in the lower left quadrant
ant are in late apoptosis, and cells in the upper left quadrant are dead. C. Cell morphology
dicated treatments. Scale bars, 50 μm.
Fig. 4. Proteasome-inhibitory effects of DDTC–Cu(I). A. Cell-free proteasomal CT-like activity assay for the indicated chemicals or their combinations. The CT-like activitywas inhibited byDDTC–
Cu(I), CuCl (DDTC + Na2SO3) or CuCl2, but was not inhibited by the other chemicals alone or their combinations, indicating that copper(I) or copper(II) is the central factor for proteasome
activity inhibition. Concentration: 10 μmol/L. *P b 0.01 versus the control. B. Proteasomal CT-like activity assay with SW1990 cells on the indicated treatments. *P b 0.01 versus the control.
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metabolisms.
Discussion
Despite the treatment modalities available for pancreatic cancer
(e.g., chemoradiation, surgery, or a combination of these), it has the
worst prognosis of all the major malignancies, with less than 5% ofFig. 5. Effects of DDTC-Cu(I) on the tumorigenesis of SW1990 cells in vivo. A. Tumor growth ch
each experimental group; bars, SD. *P b 0.01. B. Comparison of ﬁnal tumorweights after in vivo
group. Upper panel, ﬁnal weights after treatments. Columns, mean; bars, SD. C. IHC assessment
day treatment and the prepared tissue slides were used for immunostaining with NF-κB, p27 a
Scale bars for all panels, 20 μm. D. Western blot analysis of tumor tissue extracts with ubiqu
and reduced NF-κB expression were detected in the tissue extracts of tumors treated with DDTpatients alive 5 years after diagnosis. Therefore, new treatment modal-
ities for pancreatic cancer patients are urgently needed. A promising ap-
proach is the targeted therapy that is to block ubiquitin/proteasome
pathways. The complex constituted by copper and DSF attracts world-
wide interest recently for its anticancer effect as a proteasome activity
inhibitor (Chen et al., 2006; Daniel et al., 2005; Li et al., 2008; Liu
et al., 2012). Investigators discovered that DSF–Cu complex could inhib-
it proteasome activity in vitro, moreover, their studies revealed that ifart showing the effect of the treatments in vivo. Points indicate themean tumor volume in
treatments. Lower panel, representative tumor pictures of the treatment group or control
of ubiquitin, p27, NF-κB and H&E aswell as TUNEL assays. Tumors were collected after 25-
nd ubiquitin antibodies. The TUNEL assay shows apoptotic cells (brown) in tumor tissue.
itin, p27, NF-κB, or GAPDH antibodies. The accumulation of ubiquitinated proteins, p27,
C–Cu(I).
Fig. 6. Copper contents of tumors, livers, brains or kidneys of mice administered with ve-
hicle or DDTC–Cu(I) for 25 d, n = 8. Error lines are SD.
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plex in vivo. However, several kinds of complexes including DDTC–
Cu(I) and DDTC–Cu(II) might be formed when DSF is administrated to
human or animals, because DSF is metabolized to DDTC in vivo and
copper(I) as well as copper(II) exists.
Copper has a long history of medical application. Its potential an-
ticancer properties have been explored in the last few decades after
the discovery of cisplatin (Radulovic et al., 2002). A few copper com-
plexes have been found to be anticancer active and there is a huge
scope in the design of more potent but less toxic copper-based anti-
cancer drugs (Iakovidis et al., 2011; Wang and Guo, 2006). Though
many copper-based anticancer agents have proved cytotoxic
in vitro, their further utility is limited by the poor water solubility
and relatively high toxicity in vivo. Our studies focused on the func-
tion of complexes constituted by DSF and various metals primarily.
We found that reducing agents such as sodium sulﬁte may decom-
pose DSF to DDTC and form new complexes with copper(I) or
copper(II). We also found that a copper complex with a ligand of
either DSF or DDTC, has anticancer activity, however, only the com-
plex constituted by DDTC and copper(I) at ratio of 1:1 is resolved
in water. To make certain that the structure of DDTC–copper(I) was
synthesized in our study, we did a series of assays and the structure
was worked out as a binuclear complex according to the mass spec-
tra mainly (seen in Supplementary material 1).
As described above, in the studies on DSF–Cu complex, the proteasome
activity inhibition was examined in vitro, however, this effect in vivo
was examined by the protocol that DSF was injected into animals,
which is based on the possible mechanism that DSF binds copper
in vivo. Due to the various copper amounts in different tumors and
the intricate internal environment of bodies, whether DSF–copper com-
plex can be formed is unknown for an individual. As cisplatin or other
metal complexes used clinically had been prepared manually outside
bodies (Lai et al., 2011), an aqueous solution of DDTC–Cu(I) can be pro-
duced by the protocol described in this article. Unlike DSF–Cu which
needs dimethyl sulphoxide (DMSO) to facilitate dissolution (Chen
et al., 2006; Zhang et al., 2010), DDTC–Cu(I) is dissolved in water
directly.
In a previous study on DSF–Cu, the investigators described that DSF
carries copper ions into tumor cells thereby preventing copper from
interacting with many nonspeciﬁc proteins. They also theorized that
the copper is responsible for inhibiting the proteasome (Chen et al.,
2006). The cell-free proteasome activity assay in this study showed
that DDTC–Cu(I) was not more potent in inhibiting proteasome activity
than CuCl2 or CuCl (CuCl2 + Na2SO3), perhaps because the coordina-
tion of DDTC interferes with the interaction between copper ions and
the proteasome (Fig. 4A). The data support the hypothesis that it is cop-
per to inhibit proteasome activity.Wecarried out a preliminary experiment actually before the reported
in vivo experiment. In the preliminary experiment, DDTC–Cu(I) was
used without dexamethasone to mice harboring tumors. Though the
tumor growth was retarded by DDTC–Cu(I) signiﬁcantly after 21-day
management, some adverse effects such as hemafecia, anorexia, and
maransis were observed (seen in Supplementarymaterial 2), suggesting
to us the use of dexamethasone as an adjuvant drug in the formal exper-
iment. No obvious adverse effects were observed when dexamethasone
was used along with DDTC–Cu(I), which indicates that DDTC–Cu(I)
could demonstrate anticancer activity at a tolerable dosage.
The copper homeostatic mechanisms could play an important
role in the prevention of copper toxicity, while exposure to excessive
levels of copper can result in a number of adverse health effects in-
cluding liver and kidney damage, anemia, immunotoxicity, and de-
velopmental toxicity (Bonham et al., 2002). Our tissue copper
content analysis results showed that DDTC–Cu(I) treatment on
mice could increase the copper levels in tumors and other tissues
such as livers, brains as well as kidneys. Among the tissues, the cop-
per contents of tumors are higher than in the three organs, indicating
that copper was enriched in the pancreatic cancer SW1990 xenograft
tumors. However, these increases were not as dramatic as those in-
duced by copper metabolism disorders such as Wilson disease
(Suzuki, 1995; Shim and Harris, 2003). Besides, we could ﬁnd that
the copper contents in either the treated or the control group was
not beyond the normal range of the tissues (Li et al., 1991), these
might be attributed to the regulation of metabolism and/or the rea-
son that DDTC could act as an anti-copper drug.
As an essential trace element for most organisms, copper might act
as a “double-edged sword” by promoting physiological and malignant
angiogenesis. A few copper complexes exhibit anticancer potential as
proteasome inhibitors, inducing apoptosis in various types of human
cancer cells. In this study, a new binuclear complex, DDTC–Cu(I), was
synthesized with DDTC which is the monomer of DSF, copper chloride,
aswell as sodiumsulﬁte, and the data presented here support that it has
the potential to inhibit proliferation of pancreatic cancer cells in vitro
and tumor growth signiﬁcantly in vivo via inhibition of proteasome
activity.
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